By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Climbing from platform prover to biopharma player
PhaseBio is a small public company aiming to enter a large-market therapeutic area: cardiovascular. Each of its cardiovascular drugs addresses a significant unmet medical need. They include bentracimab, in a Phase 3 trial for reversing ticagrelor’s antiplatelet activity in major bleeding or to enable urgent surgery, and PB6440, an oral selective aldosterone synthase inhibitor in preclinical development for treatment-resistant hypertension. Another lead drug, pemziviptadil, a once-weekly VPAC2-selective agonist in Phase 2 for treating pulmonary arterial hypertension (PAH), is integrated with an extended-action technology, ELP (elastin-like polypeptides).